Physician profile
Michael B Goldstein
NPI 1669469581
$9,095.74
in general payments reported to CMS, 2019-2025
37 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $764 · 2021: $1,392 · 2022: $1,218 · 2023: $1,426 · 2024: $1,832 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,538 · Education: $15.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,538.18 |
| Education | $15.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,064.98 | 2019-2025 | Trulance, Xifaxan |
| Abbvie INC. | $1,667.09 | 2019-2025 | |
| Janssen Biotech, INC. | $882.15 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $748.78 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $496.64 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $334.07 | 2019-2025 | |
| Gilead Sciences, INC. | $332.30 | 2021-2025 | Livdelzi |
| Regeneron Healthcare Solutions, INC. | $255.13 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $228.37 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $200.12 | 2024-2025 | Voquezna |
| Celgene Corporation | $194.31 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $180.31 | 2019-2024 | Linzess |
| Aimmune Therapeutics, INC. | $146.29 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $135.00 | 2025 | Rezdiffra |
| Lilly USA, LLC | $130.44 | 2024-2025 | Omvoh |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $126.68 | 2019-2023 | Rebyota, Cimzia |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Celltrion USA INC. | $120.34 | 2024-2025 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $113.88 | 2019-2024 | Dificid |
| Genzyme Corporation | $93.95 | 2022-2025 | |
| Daiichi Sankyo INC. | $74.12 | 2022-2023 | Injectafer |
| Allergan, INC. | $53.97 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $49.79 | 2024-2025 | Bylvay, Iqirvo |
| Nestle Healthcare Nutrition INC. | $48.24 | 2023 | |
| Redhill Biopharma INC. | $42.86 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Boston Scientific Corporation | $40.21 | 2024 | Watchman |
| Evoke Pharma, INC. | $39.24 | 2023 | Gimoti |
| Endo Pharmaceuticals INC. | $27.22 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $19.98 | 2019 | |
| Solventum Corporation | $19.04 | 2024 | V.A.C.Ulta |
| Ge Healthcare | $16.81 | 2025 | |
| Sandoz INC. | $16.43 | 2025 | Hyrimoz |
| Pharmacosmos Therapeutics INC. | $15.71 | 2024 | Monoferric |
| Medtronic, INC. | $15.28 | 2022 | |
| Alfasigma USA, INC. | $14.20 | 2020 | |
| Intercept Pharmaceuticals, INC. | $14.19 | 2019 | |
| Braintree Laboratories, INC. | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.